

# Supplementary Table 1

ID	Site of disease	Site of biopsy	RX	% Response	Wnt5A postivity	Time of PFS
3C	sc	Skin / subcutaneous nodule biopsy	BRAF <sub>i</sub>	10%	++	10
10A	li, sc, n	Skin / subcutaneous nodule biopsy	BRAF <sub>i</sub> + MEK <sub>i</sub>	13%	+++	3 months
R5	sc, n	Skin / subcutaneous nodule biopsy	BRAF <sub>i</sub> + MEK <sub>i</sub>	17%	+	6 months
16B	sc, n	Skin / subcutaneous nodule biopsy	BRAF <sub>i</sub> + MEK <sub>i</sub>	20%	+	11 months
31A	sc,n	Skin / subcutaneous nodule biopsy	BRAF <sub>i</sub> + MEK <sub>i</sub>	22%	+	4 months*
35B	sc,n	Skin / subcutaneous nodule biopsy	BRAF <sub>i</sub> + MEK <sub>i</sub>	23%	-	8months, ongoing*
R10	n, sc	Subcutaneous nodule	BRAF <sub>i</sub> + MEK <sub>i</sub>	23%	++	3 months
R8	Lu, sc, n	Skin / subcutaneous nodule biopsy	BRAF <sub>i</sub> + MEK <sub>i</sub>	23%	-	2 months*
R4	n, sc	Lymph node	BRAF <sub>i</sub> + MEK <sub>i</sub>	33%	++	5 months
6A	sc	Skin / subcutaneous nodule biopsy	BRAF <sub>i</sub> + MEK <sub>i</sub>	38%	-	15 ongoing
R12	n, li	Hepatectomy	BRAF <sub>i</sub>	50%	++	5 months
20C	n,sc,li,lu	bowel	BRAF <sub>i</sub>	50%	+/-	2 months
R6	n, li, lu	small intestine	BRAF <sub>i</sub> + MEK <sub>i</sub>	50%	-	4 months
24A	br,sc,lu,li,n	Skin / subcutaneous nodule biopsy	BRAF <sub>i</sub>	53%	-	2 months
16A	sc, n	Skin / subcutaneous nodule biopsy	BRAF <sub>i</sub> + MEK <sub>i</sub>	57%	-	7 months ongoing
R9	n, lu	Lymph node	BRAF <sub>i</sub> + MEK <sub>i</sub>	57%	+/-	12 months, ongoing
13A	sc, n	Skin / subcutaneous nodule biopsy	BRAF <sub>i</sub> + MEK <sub>i</sub>	58%	-	9 months
6B	sc	Skin / subcutaneous nodule biopsy	BRAF <sub>i</sub> + MEK <sub>i</sub>	60%	-	22 months
R3	n, li, lu	Lymph node	BRAF <sub>i</sub> + MEK <sub>i</sub>	63%	+/-	13 months
25A	n, sc	Skin / subcutaneous nodule biopsy	BRAF <sub>i</sub> + MEK <sub>i</sub>	64%	-	3 months
11A	sc,br	Skin / subcutaneous nodule biopsy	BRAF <sub>i</sub> + MEK <sub>i</sub>	80%	-	10 months
12A	sc, br, n	Skin / subcutaneous nodule biopsy	BRAF <sub>i</sub> + MEK <sub>i</sub>	86%	-	9 months ongoing
12B	sc, br, n	Skin / subcutaneous nodule biopsy	BRAF <sub>i</sub> + MEK <sub>i</sub>	89%	-	12 months
R2	li, lu	Hepatectomy	BRAF <sub>i</sub>	90%	+/-	7 months